ClinicalTrials.gg
RecruitingNCT06550219Updated Feb 4, 2025

Evaluation of Nasal Non Invasive Ventilation in Management of Neonates With Respiratory Distress Using Lung Ultrasound

An interventional study of Nasal humidified heated high flow cannula (NHHHC) and Nasal intermittent positive pressure ventilation (NIPPV) in Preterm and Ventilator Lung; Newborn, sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to participants aged 1 Hour to 24 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
1 Hour to 24 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Premature Birth by Alexandria University — 5 open to participants now, 5 under way, none of them phase 3. Premature Birth · Alexandria University.

Planned enrollment
10th of 10
30 · median 100
Started
2024
with 2 others
No phase
8 of 10
5 open now
Registered
6th of 10
by date

Among the 10 studies in Premature Birth by Alexandria University, this one is the 10th largest by planned enrollment, is one of 3 that started in 2024, is one of 8 with no phase, and was the 6th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

5 of the 10 studies in Premature Birth by Alexandria University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 1 Hour to 24 Hours · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Premature Birth by Alexandria University, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of non-invasive ventilation (nIPPV)

, (nCPAP), and nasal high flow cannula (NHFC) as a primary mode of ventilation in preterm neonates \<37 gestational week with moderate to severe RD using LUS as regard: I. Primary outcomes: Duration of non-Invasive ventilation. II. Secondary outcomes: Evaluation LUS over the 1 st 7 days of life or weaning from ventilation. Need for intubation and invasive ventilation. Duration of respiratory support. Need for surfactant. Oxygen saturation index and oxygen index. Broncho-pulmonary dysplasia; grade. Duration of hospital stay

03

Conditions studied

  • Preterm
  • Ventilator Lung; Newborn

Keywords

  • preterm infants
  • non-invasive ventilation
04

Who can participate

Ages eligible
1 Hour to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Preterm \<37 wk. gestational age admitted to the NICU with spontaneous breathing and clinical manifestations of RD (tachypnea, nasal flaring, intercostal and subcostal retraction and or grunting).

Exclusion Criteria:

  1. Obvious major congenital abnormalities.
  2. Any of the baby intubated for resuscitation or for other reasons.
  3. Neonates need invasive mechanical ventilation.
  4. Pulmonary hemorrhage.
  5. Severe cardiovascular instability.
  6. Cardiopulmonary arrest needing prolonged resuscitation.
  7. Birth asphyxia (one-minute Apgar score ≤ 3).
  8. Major cardiac diseases (not including patent ductus arteriosus).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    nasal intermittent positive pressure ventilation group

    Device: Nasal intermittent positive pressure ventilation (NIPPV) · Device: lung ultrasound

  • Experimental
    nasal continuous positive pressure ventilation group

    Device: Nasal continuous positive airway pressure NCPAP · Device: lung ultrasound

  • Experimental
    nasal high flow cannula group

    Device: Nasal humidified heated high flow cannula (NHHHC) · Device: lung ultrasound

Interventions

  • DeviceNasal humidified heated high flow cannula (NHHHC)

    Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.

  • DeviceNasal intermittent positive pressure ventilation (NIPPV)

    Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.

  • DeviceNasal continuous positive airway pressure NCPAP

    Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.

  • Devicelung ultrasound

    Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).

06

What researchers measure

Primary outcomes

  1. Duration of non-Invasive ventilation (NIV)

    Describe the days of non-invasive ventilation , described in days number.

    Time frame: First two weeks of life.

Secondary outcomes

  1. Oxygen saturation index (OSI).

    Mean airway pressure (MAP)X Fraction of inspired oxygen (FIO2) X SPO2 ( oxygen saturation) The score of OSI is recorded twice per day for first seven days.

    Time frame: first one weeks of life.

07

Study locations

1 of 1 sites recruiting
  • Alexandria university, Elshattbi hospital
    Alexandria, 0354, Egypt
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2025, 6 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 6 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2024
First posted
Aug 12, 2024
StartActual
Nov 20, 2024
Primary completionEst.
May 28, 2025
CompletionEst.
Nov 1, 2025
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06550219
Responsible party
Marwa Mohamed Farag (Assistant professor, Alexandria University) — Principal investigator
First posted
Aug 12, 2024
Start date
Nov 20, 2024
Primary completion
May 28, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Feb 4, 2025

Study contacts

Marwa M Farag, PhD
Contact
d.marwa.farag@gmail.com
01288681788

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion